NEW
Bonspri

Bonspri

Manufacturer:

Novartis

Distributor:

DKSH
Concise Prescribing Info
Contents
Ofatumumab
Indications/Uses
Relapsing forms of multiple sclerosis (RMS) including relapsing-remitting disease & active secondary progressive disease in adults.
Dosage/Direction for Use
SC Initially 20 mg inj at wk 0, 1 & 2 followed by subsequent 20 mg inj once mthly starting at wk 4.
Contraindications
Special Precautions
Discontinue use if progressive multifocal leukoencephalopathy is confirmed; serious opportunistic or recurrent infections develops in patients w/ low Ig; prolonged hypogammaglobulinemia requiring treatment w/ IV Ig. Not to be inj into moles, scars, stretch marks, tender, bruised, red, scaly or hard skin. Increased risk of infection; HBV reactivation & infection; inj-related reactions. Perform HBV screening including HBsAg, hepatitis B core Ab & quantitative serum Ig prior to therapy. Immunogenicity. Not recommended w/ live or live-attenuated vaccines. Concomitant use w/ immunosuppressive therapy. Women of childbearing potential should use effective contraception during & at least 6 mth after last dose. Pregnancy & lactation. Childn.
Adverse Reactions
URTI, systemic inj-related reactions, headache, local inj site reactions, UTI, back pain, decreased blood IgM.
Drug Interactions
Increased risk of infection w/ immunosuppressant drugs including systemic corticosteroids. Additive immune system effects w/ immunosuppressive therapies.
MIMS Class
Immunosuppressants
ATC Classification
L04AA52 - ofatumumab ; Belongs to the class of selective immunosuppressive agents. Used to induce immunosuppression.
Presentation/Packing
Form
Bonspri soln for inj 20 mg/0.4 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in